Investment Analysis of Hims & Hers Health, Inc. (HIMS)

Exploring Bullish and Bearish Signals with DCF Valuation

Key Takeaways

Strong Growth and Market Position: HIMS exhibits exceptional growth rates exceeding 90% annually, bolstered by successful marketing campaigns and strategic market positioning in the digital health sector.
Valuation Concerns: Despite robust growth, there are significant concerns about overvaluation, with various DCF models suggesting the stock may be priced above its intrinsic value.
Investment Rating: A balanced approach suggests a "Moderate Buy" rating, considering the high growth potential alongside valuation risks.

Bullish Signals

Technical Analysis

The stock of Hims & Hers Health, Inc. has demonstrated strong bullish trends. It broke out of a cup-and-handle pattern to reach new all-time highs in early December 2024. Following this, the Moving Average Convergence Divergence (MACD) turned positive on January 16, 2025, and the Momentum Indicator moved above the 0 level on January 15, 2025, indicating a robust upward trend. Technical analysis further supports this with 26 out of 28 indicators signaling bullish momentum.

Analyst Sentiment

Analysts are generally positive about HIMS, with an average rating of "Buy" and a 12-month price target of $26.21. This reflects a consensus belief in the stock's potential to outperform the market over the next year. Needham & Company has even named HIMS their "#1 digital health pick for 2025", highlighting the company's strong market position and growth potential.

Growth and Market Position

Hims & Hers is a multi-specialty telehealth company with a growth rate over 90% annually, which underscores its strong market demand and scalability. The company has recently achieved profitability three quarters ago and has successfully expanded into the GLP-1 (weight loss medication) industry. This growth is supported by a highly successful ad campaign that has significantly increased brand awareness and customer acquisition.

Undervaluation

As of February 2025, HIMS is trading at US$37.28, which is significantly below its estimated fair value of US$68.8 based on cash flow projections. This suggests that the stock may be undervalued, presenting a potential buying opportunity for investors.

Bearish Signals

Valuation Concerns

Despite the high growth, the Discounted Cash Flow (DCF) valuation model estimates the intrinsic value of HIMS at $0.27 USD, which is significantly lower than its current market price of $60.47 USD. This discrepancy suggests that the stock might be overvalued based on future cash flow projections. Additionally, the high PE ratio of 105.32 indicates potential overvaluation compared to earnings.

Earnings Growth and Volatility

The PE Growth rating for HIMS points to worse than average earnings growth, which could concern investors focused on sustainable earnings growth. Furthermore, the stock's volatility could lead to future fluctuations, and the Fear & Greed Index, currently at 39, indicates a level of fear in the market regarding the stock's valuation.

Cash Flow and Burn Issues

Early-stage growth companies like HIMS often incur heavy spending on marketing, R&D, and expansion. The company's investments in growth initiatives have resulted in negative cash flows from financing activities, which may impact shareholder returns and raise questions about the path to sustained profitability.

Competitive and Regulatory Risks

The digital health space is highly competitive, with other incumbents and new entrants potentially intensifying competition. Additionally, evolving regulatory standards in healthcare and telehealth could create unforeseen hurdles for HIMS, posing risks to its long-term growth strategy.

Discounted Cash Flow (DCF) Analysis

DCF Model Assumptions

Given the company's current growth rate of over 90% annually, a DCF model can be constructed to estimate its intrinsic value. We will use the following assumptions:

Base Year Free Cash Flow (FCF): Assume HIMS begins with a normalized FCF of $10 million in Year 0.
Growth Rate: Assume an aggressive 90% annual growth for 5 years, reflecting current trends and the successful marketing campaign.
Transition to Sustainable Growth: After 5 years, assume growth moderates to 3% per year in perpetuity as the company captures a large share of its niche.
Discount Rate: Assume a discount rate of 10%, reflecting the risk premium for a high-growth, early-stage company and prevailing market conditions.

DCF Calculation Steps

Using the above assumptions, we can calculate the future cash flows and terminal value:

Year 1 FCF: $10M * (1 + 0.90) = $19.0M
Year 2 FCF: $19.0M * (1 + 0.90) = $36.1M
Year 3 FCF: $36.1M * (1 + 0.90) = $68.6M
Year 4 FCF: $68.6M * (1 + 0.90) = $130.4M
Year 5 FCF: $130.4M * (1 + 0.90) = $247.8M

Terminal Value at the end of Year 5 is calculated as:

\[ \text{TV} = \frac{\text{FCF5} \times (1 + \text{g_terminal})}{\text{r} - \text{g_terminal}} = \frac{$247.8M \times 1.03}{0.10 - 0.03} \approx $3,645M \]

The present value of these cash flows and the terminal value, discounted at 10%, yields an Enterprise Value of approximately $2,598 million.

Interpreting the DCF Results

This DCF model suggests an Enterprise Value of roughly $2.6 billion. If the current market capitalization (after accounting for cash/debt adjustments) is significantly below this value, the stock might appear undervalued. Conversely, if the market is pricing HIMS at over $2.6 billion, the explosive growth and attractive qualitative factors may already be built into the price, leaving little margin for error.

Value Rating

Value Rating Discussion

Given the bullish signals such as double-digit revenue growth, a very successful ad campaign, and expansion in the digital health space, HIMS presents a compelling growth story. However, the high valuation levels, potential cash flow challenges, and competitive and regulatory headwinds present significant risks.

For a growth investor with a high risk tolerance, the compelling growth story and market opportunity may justify a "BUY" (or "Overweight") rating, provided the current market cap is below the DCF-derived threshold. However, for a more risk-averse investor, the company remains speculative given its high valuation multiples and operational risks. In that case, the recommendation may lean toward "HOLD" until further clarity on the path to profitability emerges.

Based on the analysis, a balanced approach is recommended, considering HIMS a speculative buy with a value rating of "Moderate Buy." This rating acknowledges the growth potential but also the valuation risks.

Conclusion

Hims & Hers Health, Inc. (HIMS) presents a mixed picture with strong bullish signals driven by exceptional growth rates, successful marketing campaigns, and positive analyst sentiment. However, bearish signals such as potential overvaluation, earnings growth concerns, and competitive and regulatory risks warrant caution. The DCF analysis suggests that if the stock is priced below the estimated enterprise value, it may be a compelling investment for growth-oriented investors. A "Moderate Buy" rating reflects the need for investors to carefully weigh the high growth potential against the valuation risks.

References

How does Hims & Hers Health plan to sustain its high growth rate in the coming years?

What are the potential regulatory challenges facing Hims & Hers Health in the digital health sector?

How does Hims & Hers Health compare to other telehealth companies in terms of market share and growth?

Last updated February 19, 2025